Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasm Metastasis 5Prostatic Neoplasms 4Sarcoma 3Neoplasms 3Pancreatic Neoplasms 2Neuroblastoma 2Hodgkin Disease 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Urologic Neoplasms 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Soft Tissue Neoplasms 1Recurrent Uterine Sarcoma 1Recurrence 1Pharyngeal Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neurofibromatosis 2 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Mesothelial 1Mouth Neoplasms 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphangioleiomyomatosis 1Liver Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1

Interventions

temsirolimus 1ridaforolimus 1pazopanib 1Surveys and Questionnaires 1Pemetrexed 1Lenalidomide 1Crizotinib 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Advanced Cancers × temsirolimus × Clear all
NCT00877773 2016-08-25

Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients

M.D. Anderson Cancer Center

Phase 1/2 Terminated
44 enrolled 5 charts

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡